<DOC>
	<DOCNO>NCT00620607</DOCNO>
	<brief_summary>To assess response rate huC242-DM4 give intravenous infusion patient metastatic locally advanced gastric gastroesophageal junction cancer .</brief_summary>
	<brief_title>huC242-DM4 Treating Patients With Metastatic Gastric Gastroesophageal Junction Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Patients must understand voluntarily sign informed consent . Patients must histological documentation metastatic locally advanced ( American Joint Committee Cancer Staging System : Stages IIIA , IIIB , IV ) gastric gastroesophageal junction adenocarcinoma . Patients must ECOG performance status &lt; 1 . Patients must least 18 year age . Patients treat one prior chemotherapy regimen document disease progression . Patients must confirmation CanAg expression perform prior enrollment immunohistochemical assessment CanAg archive biopsy sample . Patients must measurable disease least one lesion accurately measure Response Evaluation Criteria Solid Tumors ( RECIST ) . The lesion size must least 20 mm conventional radiological technique least 10 mm spiral CT scan . Disease irradiate field site measurable disease acceptable clear progression lesion . Patients reproductive potential must agree use effective contraceptive method study 30 day receive last dose study drug . Women childbearing potential ( WCBP ) must negative urine serum pregnancy test within one week prior enrollment study . Patients must chemotherapy , immunotherapy , hormonal therapy , radiotherapy cancer surgery ( except minor surgical procedure ) complete least 3 week start study medication . Patients must resolution clinically significant toxic effect ( exclude alopecia ) prior treatment include surgery , radiotherapy , hormone therapy , immunotherapy , target noncytotoxic therapy , chemotherapy grade ≤ 1 NCI CTCAE v. 3.0 unless otherwise specify inclusion laboratory value . Patients must adequate organ function include : 1 . Hematopoietic : . Absolute neutrophil count &gt; 1,500/mm3 . ii . Platelet count &gt; 100,000/mm3 . iii . Hemoglobin &gt; 9 g/dL ( transfusion allow ) . 2 . Renal : i. Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) ii . Calculated creatinine clearance &gt; 60 mL/min/1.73m2 . 3 . Hepatic : i. Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ii . Total bilirubin ≤ 1.5 x ULN Pregnant lactate woman . Women childbearing potential ( WCBP ) must negative urine blood test pregnancy first treatment . Known hypersensitivity previous monoclonal antibody therapy maytansinoids . Active uncontrolled infection . Known history hepatitis B C , HIV , history alcoholic liver disease . Patients serious medical psychiatric disorder would interfere patient safety inform consent . Patients peripheral neuropathy grade 2 great . Patients know leptomeningeal disease progressive brain metastasis . Routine screen CNS image study ( CT MRI ) require clinically indicate . Patients concomitant malignancy previous malignancy less 2 year disease free interval time dose . Patients adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix Stage A lowgrade prostate cancer may enroll irrespective time diagnosis . Patients receive concomitant chemotherapy , immunotherapy , radiotherapy , investigational therapy . Radiotherapy palliation relate bone metastasis permit upon agreement investigator ImmunoGen Medical Monitor long radiation involve target lesion follow drug treatment response evaluation . Patients severe concurrent disease condition , judgment Investigator , would make patient inappropriate study participation . The disease condition include , limited , one following : bleeding diathesis , uncontrolled chronic kidney liver disease , uncontrolled diabetes , history cardiac disease , myocardial infarction within past 6 month , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled hypertension . Patients must use contact lens discontinue use contact lenses course clinical study . Patients must discontinue use contact lenses prior receive study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>gastric</keyword>
</DOC>